
    
      Duration: 24 week-intervention Study Group: Four arms

        -  Control: no intervention

        -  Rosiglitazone: rosiglitazone (8 mg/day)

        -  alpha-lipoic acid: alpha-lipoic acid (1800 mg/day)

        -  Rosiglitazone/alpha-lipoic acid: combination of rosiglitazone (8 mg/day) and
           alpha-lipoic acid (1800 mg/day)
    
  